Thyroid Eye Disease
📧 Sign up to get email alerts when something new happens for Thyroid Eye Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-03-16Clinical Trial Update: Triamcinolone Acetonide Injection for Upper Eyelid Retraction in Thyroid Eye Disease [NA]
A completed clinical trial evaluating Triamcinolone Acetonide Injection for upper eyelid retraction in Thyroid Eye Disease. The study was sp…
-
CLINICAL_TRIALS trial_result · 2026-03-16Clinical Trial Update: A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease. [Phase 3]
A Phase 3 trial evaluating subcutaneous efgartigimod (PH20 SC) for adults with Thyroid Eye Disease has been terminated.
-
CLINICAL_TRIALS trial_result · 2026-03-10Clinical Trial Update: An Efficacy and Safety Study of NTB003 in Participants With Thyroid Eye Disease (TED) [Phase 1, Phase 2]
This document notes a Phase 1/2 clinical trial evaluating NTB003 for thyroid eye disease, which is currently not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2026-03-09Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease [Phase 2]
A Phase 2 study evaluating the efficacy and safety of LASN01 in Thyroid Eye Disease (Graves' ophthalmopathy) has completed and results are p…
-
CLINICAL_TRIALS trial_result · 2026-03-02Clinical Trial Update: Psychological Burden of Thyroid Eye Disease
This entry reports the completion of a clinical trial examining the psychological burden associated with Thyroid Eye Disease.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease. [NA]
A clinical trial update indicating that Teprotumumab N01 is being studied to evaluate its efficacy and safety in patients with Thyroid Eye D…
-
CLINICAL_TRIALS trial_result · 2026-02-18Clinical Trial Update: Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease [Phase 3]
An extension-phase 3 study of batoclimab for Thyroid Eye Disease is listed as active but not recruiting. This document serves as a status up…
-
CLINICAL_TRIALS trial_result · 2026-02-18Clinical Trial Update: A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED) [Phase 3]
A randomized Phase 3 trial evaluating VRDN-001 for Thyroid Eye Disease has completed, including safety and tolerability assessments.
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease [Phase 3]
A Phase 3 trial is evaluating satralizumab for Thyroid Eye Disease, with the study currently listed as ACTIVE_NOT_RECRUITING.
-
CLINICAL_TRIALS trial_result · 2026-02-12Clinical Trial Update: An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301 [Phase 3]
This document reports the completion of an open-label Phase 3 study for non-responders to VRDN-001-101 and VRDN-001-301 in Thyroid Eye Disea…
-
CLINICAL_TRIALS trial_result · 2026-02-11Clinical Trial Update: A Study of VV-14305 for the Treatment of Thyroid Eye Disease [Phase 1, Phase 2]
A Phase 1/2 clinical trial update for VV-14305 in Thyroid Eye Disease, sponsored by Kriya Therapeutics; the study is not yet recruiting.
-
CLINICAL_TRIALS research · 2026-02-11Clinical Trial Update: A Study of GenSci098 in Subjects With Active Thyroid Eye Disease [Phase 1]
A Phase 1 study evaluating GenSci098 in adults with active thyroid eye disease is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-02-03Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease [Phase 3]
A Phase 3 study evaluating the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab in patients with Thyroid Eye Disease…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease [Phase 3]
This clinical trial update describes a Phase 3 study comparing subcutaneous teprotumumab with placebo in adults with moderate-to-severe acti…
-
CLINICAL_TRIALS trial_result · 2026-01-15Clinical Trial Update: TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study [Phase 4]
Phase 4 post-marketing requirement study for TEPEZZA (teprotumumab-trbw) in Thyroid Eye Disease has completed.
-
CLINICAL_TRIALS trial_result · 2026-01-14Clinical Trial Update: OCT Angiography Drived Alterations in Thyroid-associated Orbitopathy
Completed clinical trial investigating OCT Angiography-derived alterations in Thyroid eye disease (thyroid-associated orbitopathy).
-
CLINICAL_TRIALS trial_result · 2026-01-14Clinical Trial Update: A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) [Phase 3]
Phase 3 safety, tolerability and pharmacokinetics study of VRDN-003 in participants with Thyroid Eye Disease; the trial is currently active …
-
CLINICAL_TRIALS research · 2025-12-30Clinical Trial Update: Comparison of the Efficacy and Safety of 4 vs. 8 Treatments With Tepezza (Teprotumumab) for Thyroid Eye Disease [Phase 4]
Phase 4 clinical trial comparing 4 versus 8 Tepezza treatment regimens for Thyroid Eye Disease. The trial is currently not yet recruiting.
-
CLINICAL_TRIALS research · 2025-12-29Clinical Trial Update: A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease [Phase 3]
A Phase 3 clinical trial evaluating the efficacy and safety of ZL-1109 in Chinese participants with active Thyroid Eye Disease is currently …
-
CLINICAL_TRIALS research · 2025-12-04Clinical Trial Update: A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease [Phase 4]
Clinical trial update for Teprotumumab N01 in active thyroid eye disease is listed as Phase 4 and not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2025-12-03Clinical Trial Update: Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease [Phase 3]
A Phase 3 trial evaluating batoclimab for active thyroid eye disease has completed.
-
FDA approval · 2025-11-24FDA Approved: TEPEZZA — Supplemental Application (Horizon Therapeutics USA, Inc.)
FDA approved a supplemental application for Tepezza (teprotumumab) from Horizon Therapeutics USA, Inc., potentially expanding its indication…
-
CLINICAL_TRIALS research · 2025-11-17Clinical Trial Update: A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease [Phase 3]
A Phase 3 clinical trial is evaluating the efficacy and safety of IBI311 in inactive thyroid eye disease and is currently recruiting. Sponso…
-
CLINICAL_TRIALS trial_result · 2025-10-23Clinical Trial Update: An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) (THRIVE-2) [Phase 3]
A Phase 3 clinical trial THRIVE-2 evaluating Veligrotug (VRDN-001) for chronic Thyroid Eye Disease has completed.
-
CLINICAL_TRIALS trial_result · 2025-10-03Clinical Trial Update: A Study of IBI311 in Subjects With Inactive or Active Thyroid Eye Disease [Phase 2]
A Phase 2 clinical trial evaluating IBI311 in patients with Thyroid Eye Disease has completed. The update notes the study status but does no…